Skip to main content
Theranexus logo

Theranexus — Investor Relations & Filings

Ticker · ALTHX ISIN · FR0013286259 LEI · 969500BFCV6IC7MFQP20 PA Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2019-03-26 Regulatory Filings
Country FR France
Listing PA ALTHX

About Theranexus

https://www.theranexus.com/en/

THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.

Recent filings

Filing Released Lang Actions
THERANEXUS TO PRESENT NEW SCIENTIFIC DATA ON DRUG CANDIDATE THN201 AT AD/PD 2019, THE 14TH CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES LISBON, 26-31 MARCH 2019
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Theranexus will present new scientific data regarding its drug candidate THN201 at the AD/PD 2019 conference. It details the scientific findings, the status of the Phase Ib trial (mentioning results expected by the end of 2019), and provides company background. This content is characteristic of an announcement intended for investors and the scientific community, focusing on research progress and upcoming presentations, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a formal Investor Presentation (IP) document itself. Since it is a press release detailing research progress and upcoming conference participation, it most closely aligns with general Investor Relations material. Given the options, 'Investor Presentation' (IP) is often used for detailed slides, while this is a narrative announcement. However, since it is a detailed update on drug development and trial status aimed at investors, and not a formal regulatory report or a transcript, it fits best under the general umbrella of investor communication. If a specific 'Press Release' category existed, that would be ideal. Lacking that, and given the depth of the scientific and trial update, 'Investor Presentation' (IP) is a plausible fit for substantive investor communication, although 'Regulatory Filings' (RNS) is a fallback. Considering the content is a detailed narrative update on R&D progress, I will classify it as an Investor Presentation (IP) as it serves that function, even if it's not a slide deck.
2019-03-26 English
THERANEXUS ANNOUNCES PRELIMINARY RESULTS OF PHASE II TRIAL OF THN102 ON NARCOLEPSY PATIENTS
Earnings Release Classification · 99% confidence The document is a press release dated February 27, 2019, announcing the preliminary results of a Phase II clinical trial (THN102 on Narcolepsy patients) and providing updates on other ongoing clinical trials (THN102 in Parkinson's, THN201 in Alzheimer's, THN101 for neuropathic pain) and R&D platform progress (Neurolead). It also explicitly states the date for the next financial publication: 'Monday April 29, 2019 (before market opening): 2018 annual financial results'. This structure—announcing clinical trial progress, pipeline updates, and future financial report dates—is characteristic of an Investor Presentation (IP) or a general corporate update, rather than a formal regulatory filing like a 10-K or an Earnings Release (ER) which focuses solely on period results. Since it is a detailed presentation of strategy, pipeline, and market potential, Investor Presentation (IP) is the most appropriate classification. FY 2019
2019-02-27 English
THERANEXUS ANNONCE LES RÉSULTATS PRÉLIMINAIRES DE L'ÉTUDE DE PHASE 2 DU THN102 DANS LA NARCOLEPSIE
Earnings Release Classification · 99% confidence The document is a press release dated February 27, 2019, announcing the preliminary results of a Phase 2 clinical study (THN102 in narcolepsy). It details clinical trial outcomes, future development plans for other assets (Parkinson's, Alzheimer's, neuropathic pain), and concludes with a section titled "Prochaine publication financière: Lundi 29 avril 2019 (avant bourse) : Résultats financiers annuels 2018". This structure—announcing key operational/clinical news while also flagging the upcoming release of formal annual financial results—is characteristic of an Earnings Release (ER) or a general operational update that precedes the full annual report (10-K). Since the document itself is focused on clinical trial results and pipeline updates rather than the detailed financial statements of the full year, and it is an announcement of results (albeit clinical ones), it aligns best with the Earnings Release (ER) category, which covers initial announcements of periodical financial results and key operational highlights. It is not the full 10-K, nor is it just a notice about the release date (RPA). FY 2018
2019-02-27 French
THERANEXUS REPORTS CASH POSITION AS OF 31 DECEMBER 2018 AND PROVIDES UPDATE ON CURRENT STATUS OF ACTIVITIES
Earnings Release Classification · 98% confidence The document is titled "THERANEXUS REPORTS CASH POSITION AS OF 31 DECEMBER 2018 AND PROVIDES UPDATE ON CURRENT STATUS OF ACTIVITIES" and is dated February 13, 2019. It provides a summary of the year-end cash position (€15.2M) and updates on ongoing clinical trials (THN102, THN201, THN101) and platform development (Neurolead). This content structure—a brief financial summary combined with operational updates for a specific period (year-end 2018)—is characteristic of an Earnings Release (ER), which typically announces key financial highlights before the full report. Crucially, the document explicitly states: "Monday, April 29, 2019 (before market opening): 2018 annual financial results." This confirms that the full annual results (10-K equivalent) are forthcoming, making this document the preliminary announcement of results, which aligns with the Earnings Release (ER) definition. FY 2018
2019-02-13 English
THERANEXUS PUBLIE SA TRÉSORERIE AU 31 DÉCEMBRE 2018 ET PRÉSENTE UN POINT SUR L'AVANCEMENT DE SES ACTIVITÉS
Earnings Release Classification · 98% confidence The document is titled "THERANEXUS PUBLIE SA TRÉSORERIE AU 31 DÉCEMBRE 2018 ET PRÉSENTE UN POINT SUR L'AVANCEMENT DE SES ACTIVITÉS" (Theranexus publishes its cash position as of December 31, 2018, and provides an update on the progress of its activities). It details the cash position at year-end 2018, provides updates on ongoing clinical trials (THN102, THN201, THN101), and mentions the upcoming release of the full 2018 annual financial results on April 29, 2019. This content—a summary of financial position and operational progress released before the full annual report—is characteristic of an Earnings Release (ER), which typically provides key highlights for a period. It is not the comprehensive 10-K, nor is it a transcript (CT) or a formal audit report (AR). Since it explicitly announces the cash position and operational milestones for the period ending December 31, 2018, it fits the definition of an Earnings Release (ER). FY 2018
2019-02-13 French
THERANEXUS set to receive EUR 6.2 million in funding from the French Investments for the Future program, managed by Bpifrance, for the development of Neurolead, its new lead generation platform target
Capital/Financing Update Classification · 98% confidence The document is a press release dated January 29, 2019, announcing that Theranexus has been awarded €6.2 million in funding from the French Investments for the Future program (PIA) managed by Bpifrance for its Neurolead platform development. This announcement details a significant financing event, collaboration partners (Collège de France, CEA), and the strategic importance of the funding. This content aligns directly with the definition of 'Capital/Financing Update' (CAP), as it is an announcement about receiving substantial funding/financing for R&D projects. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), but a specific announcement about capital inflow.
2019-01-29 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.